Mega Lifesciences (MEGA) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached 3,408 million Baht, up from 3,208 million Baht year-over-year.

• Net profit attributable to owners was 604.5 million Baht, a significant increase from 449.8 million Baht in Q1 2025.

• Total comprehensive income for the period was 721.0 million Baht, compared to 441.4 million Baht in Q1 2025.

Financial highlights

• Gross profit for Q1 2026 was 1,784 million Baht, with cost of sales at 1,624 million Baht.

• Basic earnings per share rose to 0.69 Baht from 0.52 Baht year-over-year.

• Cash and cash equivalents increased to 4,281 million Baht as of 31 March 2026, up from 4,273 million Baht at year-end 2025.

• Total assets grew to 16,030 million Baht from 15,759 million Baht at year-end 2025.

• Equity attributable to owners increased to 10,506 million Baht from 10,215 million Baht at year-end 2025.

Outlook and guidance

• The company reported strong operating cash flows and increased profitability, indicating positive momentum for the upcoming quarters.